A Randomised, Open-Label, Phase III Study Of RPR1089881 IV Every Three Weeks Versus Capecitabine (Xeolda) Tablets Twice Daily For Two Weeks In Three Week Cycles In Patients With Metastatic Breast Cancer Progressing After Taxanes. (Aventis)

Short title	A Randomised, Open-Label, Phase III Study Of RPR1089881 IV Every Three Weeks Versus Capecitabine (Xeolda) Tablets Twice Daily For Two Weeks In Three Week Cycles In Patients With Metastatic Breast Cancer Progressing After Taxanes. (Aventis)
Status	Finished
Effective start/end date	1/01/05 → 31/12/07

Project Details